Brief: Intelgenx Announces Resubmission Of Rizaport New Drug Application
Sept 26 (Reuters) - Intelgenx Technologies Corp IGX.V :
* INTELGENX ANNOUNCES RESUBMISSION OF RIZAPORT® NEW DRUG
APPLICATION
* INTELGENX TECHNOLOGIES - RESUBMITTED ITS 505(B)(2) NEW
DRUG
APPLICATION FOR RIZAPORT VERSAFILM FOR TREATMENT OF ACUTE
MIGRAINES TO U.S. FDA
Source text for Eikon: ID:nGNXbPvwZG
Further company coverage: IGX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA